Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609561 | 0.81 | NOS1 (0.46) | NOS1RAB9AFDPSSMN1; SMN2NPC1 | |
| SCHEMBL14151845 | 0.79 | NOS1 (0.50) | NOS1RAB9AFDPSSMN1; SMN2NPC1 | |
| SCHEMBL23870074 | 0.78 | NOS1 (0.36) | NOS1RAB9AFDPSSMN1; SMN2 | |
| SCHEMBL22744503 | 0.78 | NOS1 (0.36) | NOS1RAB9AFDPSSMN1; SMN2 | |
| SCHEMBL26066985 | 0.77 | NOS1 (0.43) | NOS1RAB9AFDPSSMN1; SMN2CNR2 | |
| SCHEMBL26195406 | 0.77 | NOS1 (0.43) | NOS1RAB9AFDPSCNR2KDR | |
| SCHEMBL129440 | 0.77 | MLYCD (0.40) | NOS1FDPS | |
| SCHEMBL17922323 | 0.77 | NOS1 (0.35) | NOS1RAB9A | |
| SCHEMBL17920928 | 0.77 | NOS1 (0.35) | NOS1RAB9A | |
| SCHEMBL20692099 | 0.76 | NOS1 (0.32) | NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| EP-3658538-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-11203579-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2021-12-21 | — | — | US | disclosed |
| US-20210171477-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2021-06-10 | — | — | US | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
| EP-1436290-B1 | ALKYNE-ARYL-NAPHTHYRIDIN-4(1H)-0NE DERIVATIVES AS TYPE IV PHOSPHODIESTERASE INHIBITOR | MERCK FROSST CANADA LTD (CA) | 2013-09-18 | — | — | EP | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| WO-2004047836-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004021987-A2 | TREATMENT OF RHEUMATOID ARTHRITIS BY INHIBITION OF PDE4 | MERCK & CO., INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2003018579-A1 | ALKYNE-ARYL PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NOS1 1263/4885RAB9A 2131/4885FDPS 145/4885 |
| US-11203579-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP3, NLRP1, IAPP | NOS1 2064/4885RAB9A 1435/4885FDPS 892/4885 |
| US-20210171477-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP3, NLRP1, IAPP | NOS1 2064/4885RAB9A 1435/4885FDPS 892/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NOS1 1307/4885RAB9A 2135/4885FDPS 113/4885 |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | NOS1 1052/4885RAB9A 1335/4885FDPS 656/4885 |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | CHRM3, GPR65, GPR34 | NOS1 546/4885RAB9A 3699/4885FDPS 2659/4885 |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | NOS1 1263/4885RAB9A 2131/4885FDPS 145/4885 |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | NOS1 1834/4885RAB9A 290/4885FDPS 31/4885 |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NOS1 1433/4885RAB9A 2481/4885FDPS 202/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | NOS1 1066/4885RAB9A 2999/4885FDPS 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.